Class Action Cases

Join the case to recover your losses. Click "Join this Class Action" above.

Attorneys

Entrada Therapeutics, Inc.

Join Class Action »

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Entrada announced “topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE-44-201 clinical study,” on May 7, 2026. The Company characterized the results as “positive,” but they demonstrated only a slight increase in production of a protein critical for muscle protection in Duchenne patients, well below the improvement that would result in its drug being competitive in the market. Based on this news, shares of Entrade fell by nearly 57.3% on the same day.

Press Release

TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Los Angeles, May 17, 2026  — The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Entrada Therapeutics, Inc. (“Entrada” or “the Company”) (NASDAQ: TRDA) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Entrada announced “topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE-44-201 clinical study,” on May 7, 2026. The Company characterized the results as “positive,” but they demonstrated only a slight increase in production of a protein critical for muscle protection in Duchenne patients, well below the improvement that would result in its drug being competitive in the market. Based on this news, shares of Entrade fell by nearly 57.3% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.

310-301-3335

info@schallfirm.com

www.schallfirm.com

Cases

  • This field is for validation purposes and should be left unchanged.
  • Drop files here or
    Accepted file types: xls, xlsx, doc, pdf, jpg, jpeg, Max. file size: 2 GB, Max. files: 5.
      You may redact your account numbers from your uploaded documents. The Schall Law Firm is committed to protecting the privacy of confidential information. Your documents will be securely held in AWS S3 and will only be used as proof of your transactions in connection with this matter.
    • Purchases
    • MM slash DD slash YYYY
    • If fractional shares, please round to the nearest whole number.
    • Sales
    • MM slash DD slash YYYY
    • By submitting your information, you acknowledge that this form does not create an attorney-client relationship between yourself and The Schall Law Firm. Any information you submit will be maintained as confidential. The Schall Law Firm, in its sole discretion, will contact you if it requires further information from you.